What Do Peptides Do for Your Skin? Benefits, Types, and Results

Key Takeaways

• Compounds covered: Signal peptides (pal-KTTKS/Matrixyl), carrier peptides (GHK-Cu), neurotransmitter-inhibitor peptides (argireline), oral collagen peptides, acetyl tripeptide-30 citrulline
• Goal area: Skin collagen support, hydration, barrier repair, anti-aging, wrinkle reduction
• Evidence range: Ranges from RCTs (pal-KTTKS, argireline, oral collagen meta-analyses) to in vitro studies (GHK-Cu mechanism) and gene-level fibroblast data (COL1A1 expression)
• Regulatory range: Topical cosmetic peptides regulated under FDA cosmetics law; oral collagen as dietary supplement; injectable GHK-Cu not FDA-approved and placed in FDA Category 2 as of April 22, 2026 (not eligible for 503A compounding)
• Key biomarkers for injectable peptide use: IGF-1, comprehensive metabolic panel, CBC, hs-CRP
• As of April 2026: Topical cosmetic peptides and oral collagen supplements are unaffected by recent FDA reclassifications. Injectable GHK-Cu has been placed in FDA Category 2 as of April 22, 2026, and is no longer eligible for compounding under Section 503A.
• Bottom line: Collagen-stimulating signal peptides (pal-KTTKS) and expression-line-targeting argireline have among the more robust topical RCT evidence in the cosmetic peptide category; oral collagen peptides are supported by meta-analyses of 26 RCTs for hydration and elasticity.

Understanding What Peptides Do for Skin: The Biology

The question "what do peptides do for skin?" has four distinct answers depending on the class of peptide. They are not interchangeable, and understanding why requires understanding how the skin ages.

The dermis — the connective tissue layer below the epidermis — is primarily composed of collagen fibrils, elastin fibers, and the glycosaminoglycan matrix produced and maintained by fibroblasts. Collagen provides tensile strength; elastin provides recoil; the proteoglycan matrix retains water and provides volume. These components decline with age through two converging mechanisms: intrinsic aging reduces fibroblast proliferative capacity and output, while extrinsic aging (UV radiation, environmental stress) elevates matrix metalloproteinase (MMP) activity that actively degrades the existing matrix.

Fisher and colleagues, publishing in the Journal of Cell Communication and Signaling in 2018, reframed skin aging as a failure of fibroblast-ECM interaction — when collagen fragments, fibroblasts lose mechanical tension, reduce synthesis, and increase MMP output in a positive-feedback loop. This is the cellular context that makes peptides mechanistically relevant: each of the four cosmetic peptide classes intervenes at a different point in this degradation cycle.

Gorouhi and Maibach, in their 2009 review in the International Journal of Cosmetic Science, established the four-class taxonomy still used today: signal peptides are proposed to stimulate fibroblast collagen synthesis; carrier peptides deliver mineral cofactors; neurotransmitter-inhibitor peptides are described as reducing muscular wrinkle formation; enzyme-inhibitor peptides protect existing matrix from MMP degradation. ("Cosmeceutical" is an industry term; the FDA recognizes only cosmetics and drugs as regulatory categories.) Oral and injectable peptide routes provide systemic access to these mechanisms, with different evidence bases than topical application.

The cosmetic peptide mechanisms described below are drawn from the scientific literature and describe proposed biological activity. In the United States, topical peptides sold as cosmetics are regulated under FD&C Act cosmetic provisions and are not approved by the FDA to treat, cure, or prevent any skin condition. Structural and functional claims in this article describe ingredient-level biology, not product-level drug effects.

Peptides Studied for Skin Benefits: A Quick Comparison

The following peptide compounds and routes have published evidence relevant to the skin benefits covered in this article. Ordered by strength of clinical evidence.

• Compound: Oral hydrolyzed collagen peptides
  Mechanism for skin: Systemically absorbed collagen-derived di- and tripeptides stimulate fibroblast collagen synthesis and increase dermal collagen density
  Evidence: Meta-analysis of 26 RCTs — significant improvements in skin hydration and elasticity
  FDA status: Dietary supplement regulated under DSHEA; not evaluated as a drug
  Availability: Widely available over-the-counter as a dietary supplement. Not offered through Superpower.
  Route: Oral
• Compound: Palmitoyl pentapeptide (pal-KTTKS / Matrixyl)
  Mechanism for skin: Signal peptide that stimulates fibroblast production of collagen I, III, and fibronectin
  Evidence: 12-week double-blind split-face RCT — significant wrinkle/fine line reduction
  FDA status: Cosmetic ingredient; not evaluated or approved as a drug
  Availability: Widely available over-the-counter as a cosmetic ingredient. Not offered through Superpower.
  Route: Topical
• Compound: Argireline (acetyl hexapeptide-3)
  Mechanism for skin: Neurotransmitter-inhibitor; proposed partial SNARE complex modulation associated with reduced expression-line contribution
  Evidence: Clinical study — wrinkle-depth improvements exceeding placebo over the study period
  FDA status: Cosmetic ingredient; not evaluated or approved as a drug
  Availability: Widely available over-the-counter as a cosmetic ingredient. Not offered through Superpower.
  Route: Topical
• Compound: GHK-Cu (copper tripeptide-1) — topical
  Mechanism for skin: Carrier peptide delivering copper for collagen/elastin synthesis and antioxidant defense
  Evidence: In vitro collagen synthesis; ex vivo synergy with HA for collagen IV upregulation; limited topical RCT data
  FDA status: Cosmetic ingredient; not evaluated or approved as a drug
  Availability: Widely available over-the-counter as a cosmetic ingredient. Not offered through Superpower.
  Route: Topical
• Compound: GHK-Cu — injectable
  Mechanism for skin: Systemic copper peptide with gene expression modulation across collagen synthesis, antioxidant, anti-inflammatory, and wound repair pathways (proposed mechanisms from preclinical and in vitro models)
  Evidence: Preclinical and in vitro studies only; no adequate and well-controlled human clinical trials for any skin indication
  FDA status: Not FDA-approved. Placed in FDA Category 2 (April 22, 2026); not eligible for 503A compounding. Availability through licensed compounding pharmacies is restricted.
  SP availability: Not available through Superpower
  Route: Subcutaneous injection

What Peptides Do for Skin: Individual Benefit Profiles

The four primary skin benefits attributed to peptides — collagen support, hydration, barrier repair, and anti-aging effects on wrinkles — each have a distinct biological mechanism and a distinct evidence base. What follows covers each separately.

Collagen stimulation

Stimulation of fibroblast collagen synthesis is among the most extensively investigated peptide benefits for skin. Signal peptides achieve this by mimicking the matrikine fragments produced when collagen is enzymatically degraded — these fragments act as feedback signals instructing fibroblasts to produce new matrix. Synthetic analogs like pal-KTTKS deliver the same signal without requiring prior matrix degradation.

At the gene-expression level, Dierckx and colleagues published evidence in Frontiers in Medicine in 2024 demonstrating that collagen peptides increase expression of COL1A1 (collagen type I), ELN (elastin), and VCAN (versican) in human dermal fibroblasts in culture. [In vitro] This is direct molecular evidence that peptide exposure changes the transcriptional output of fibroblasts toward matrix synthesis. Zague and colleagues, publishing in Cell Biology International in 2018, further showed that collagen peptides modulate ECM metabolism in both sun-protected and sun-exposed fibroblasts — relevant because photodamaged and chronologically aged skin both show impaired fibroblast function through the same mechanism, just with different relative contributions of MMP activity. [In vitro]

In clinical evidence, Robinson and colleagues' 12-week split-face RCT of pal-KTTKS, published in the International Journal of Cosmetic Science in 2005, reported significant reductions in wrinkle and fine line measurements at 3 ppm concentration. [RCT]

Hydration

Peptides support skin hydration through two distinct pathways: upregulation of water transport channels (aquaporins) and stimulation of natural moisturizing factor (NMF) synthesis.

Aquaporin-3, expressed in keratinocytes, is a transmembrane channel that facilitates water movement across the epidermis. Liu and colleagues published evidence in the International Journal of Pharmaceutics in 2024 reporting increased aquaporin-3 expression with acetyl tripeptide-30 citrulline, a mechanism relevant to transepidermal water regulation. [In vitro]

For systemic peptide delivery, Miyanaga and colleagues published a randomized double-blind placebo-controlled trial in Skin Pharmacology and Physiology in 2021 showing oral collagen peptides were associated with higher NMF content in the stratum corneum, a change that correlates with measured hydration improvements. [RCT] This mechanism is distinct from topical moisturization — it modifies the skin's inherent water-retention biology rather than adding an exogenous moisture barrier.

The strongest aggregate evidence for peptide hydration benefits is from oral collagen: Pu and colleagues' 2023 meta-analysis of 26 RCTs published in Nutrients found hydrolyzed collagen was associated with improvements in skin hydration and elasticity. [Meta-analysis of 26 RCTs] Asserin and colleagues, publishing in the Journal of Cosmetic Dermatology in 2015, further showed that oral collagen peptides were associated with higher dermal collagen density and improved skin moisture measures in an RCT and ex vivo model. [RCT + ex vivo]

Barrier repair

Skin barrier function depends on two complementary systems: the epidermal lipid bilayer (composed of ceramides, fatty acids, and cholesterol) and the underlying ECM that provides the structural foundation for keratinocyte function. Peptides primarily address the ECM dimension.

Khavinson and colleagues, in a 2016 study in Bulletin of Experimental Biology and Medicine, demonstrated that peptides inhibit MMP-9 synthesis in aging fibroblasts and enhance cell proliferation markers — both relevant to barrier function, since MMP-9 degrades components of the basement membrane zone that anchors the epidermis to the dermis. [In vitro]

Jeong and colleagues published evidence in the International Journal of Molecular Sciences in 2019 reporting wrinkle-depth reductions with a basement-membrane-targeting peptide complex, illustrating a mechanism relevant to dermal-epidermal junction integrity. [Clinical study]

For the lipid barrier component, ceramide-containing formulations address the epidermal lipid matrix more directly than peptides. The two approaches are complementary: peptides support ECM-level structural repair, ceramides support lipid-barrier-level repair, and comprehensive barrier restoration typically benefits from both. As Schild and colleagues reviewed in the International Journal of Cosmetic Science in 2024, ceramide content and formulation significantly determine barrier function outcomes in clinical use.

Anti-aging effects on wrinkles and expression lines

Wrinkles arise through two distinct mechanisms: structural loss of dermal collagen and elastin (volume wrinkles) and repetitive facial muscle contractions (expression lines). Peptides address both, but through different classes.

Signal peptides target structural wrinkles by stimulating collagen synthesis. Bauza and colleagues, publishing in the International Journal of Tissue Reactions in 2004, reported anti-wrinkle effects with a collagen-like topical peptide in an in vivo study. [In vivo study] Pickart and colleagues in a 2018 Biomolecules review catalogued preclinical and in vitro findings on GHK-Cu across collagen synthesis, antioxidant pathways, and wound-repair models. These findings have not been established in adequate and well-controlled human clinical trials. [Review]

For expression lines, argireline has been studied for effects on skin appearance consistent with reduced expression-line contribution. In a 2013 clinical study by Wang and colleagues, an argireline-containing formulation showed wrinkle-depth improvements exceeding those seen with placebo over the study period. A 12-week study by Gold and colleagues published in the Journal of Cosmetic Dermatology in 2022 reported that combining HA serum with a peptide-rich cream was associated with improvements in texture, tone, and wrinkle depth at 12 weeks across both face and neck. [12-week clinical study]

A 2023 systematic review and meta-analysis by Dewi and colleagues in Cureus explored outcomes from hydrolyzed collagen supplementation for skin rejuvenation, providing an up-to-date summary of what users can realistically expect: measurable improvements in skin hydration and elasticity at 8 to 12 weeks, with structural collagen changes developing over longer supplementation periods. [Systematic review]

Regulatory Status at a Glance

As of April 2026, the peptide compounds discussed in this article carry the following regulatory statuses:

• Palmitoyl pentapeptide (pal-KTTKS/Matrixyl): Cosmetic ingredient regulated under FDA cosmetics law. No prescription required.
• Argireline (acetyl hexapeptide-3): Cosmetic ingredient regulated under FDA cosmetics law. No prescription required.
• GHK-Cu (topical): Cosmetic ingredient regulated under FDA cosmetics law. No prescription required.
• GHK-Cu (injectable): Not FDA-approved for any indication. As of April 22, 2026, placed in FDA Category 2 and no longer eligible for compounding under Section 503A. Not available through Superpower.
• Oral hydrolyzed collagen peptides: Dietary supplements regulated under DSHEA. No prescription required. Not evaluated as drugs.
• Acetyl tripeptide-30 citrulline: Cosmetic ingredient regulated under FDA cosmetics law. No prescription required.

Considerations When Comparing Peptides for Skin

Peptides for skin span topical cosmetics, dietary supplements, and injectable compounded compounds. These are not equivalent categories and should not be evaluated under the same framework. Direct comparisons between a topical cosmetic peptide and an injectable compounded peptide are not meaningful — they have different mechanisms, different regulatory statuses, different evidence bases, and different risk profiles.

Your specific skin concern: Volume loss and fine lines from reduced structural support suggest signal peptides or carrier peptides. Expression lines and crow's feet suggest neurotransmitter-inhibitor peptides. Dry skin and barrier impairment suggest hydration-pathway peptides (aquaporin-targeting signal peptides, oral collagen for NMF). Peptide class determines mechanism — not all peptides address the same concern.

Evidence level: Among topical peptides, the most robust clinical evidence comes from pal-KTTKS (12-week RCT) and argireline (clinical study). For oral peptides, the meta-analysis of 26 RCTs on hydrolyzed collagen for hydration and elasticity represents the largest pooled evidence base. Many individual cosmetic peptide ingredients have only in vitro or limited clinical data. Ashaolu, in a 2025 review in the Journal of Zhejiang University Science B, summarized current evidence for bioactive peptide applications in cosmeceuticals, confirming that evidence quality varies substantially across specific ingredients.

Route and bioavailability: Topical application delivers localized effects dependent on penetration. Oral supplementation delivers systemic effects dependent on digestion and absorption. Injectable administration delivers systemic effects with higher bioavailability and different pharmacokinetics. Route selection affects which skin compartments are affected and what evidence base applies.

Formulation quality: For topical peptides, the evidence for penetration and efficacy was generated with specific formulations at specific concentrations. A product listing a peptide name without disclosing concentration, vehicle, or stability testing may not replicate the clinical outcomes from which the evidence was generated.

Safety Considerations

Topical cosmetic peptides and oral collagen peptides are generally well-tolerated. Neither category is associated with the irritation or photosensitization effects of retinoids or exfoliating acids. Lupo and Cole, in a 2007 systematic overview of cosmeceutical peptides in the Journal of the American Academy of Dermatology, reviewed clinical evidence for topical peptides noting that tolerability is a comparative advantage of the category relative to other active skincare ingredients.

Injectable peptide therapy requires clinical supervision and carries a different safety profile. Side effects depend on the specific compound, formulation, and individual response. No blanket safety statement applies across injectable peptides as a class.

Because no FDA-approved injectable peptide exists for skin indications, there is no standardized labeling. Clinicians generally consider the following contraindications when evaluating injectable peptide approaches:

• Pregnancy or breastfeeding — safety not established for any injectable peptide in this context
• Active or history of hormone-sensitive malignancy — theoretical concern with compounds that modulate growth factor signaling
• Known hypersensitivity to any component of the specific compounded formulation

For compound-specific safety information, see the individual compound pages.

What to Test Before Starting Injectable Peptide Therapy for Skin

Topical cosmetic peptides and oral collagen supplements do not require laboratory monitoring. For any injectable peptide approach, baseline biomarker testing establishes the reference points that make response assessment and safety monitoring possible.

• IGF-1: Reflects GH axis activity and growth factor signaling. Testing IGF-1 before any injectable peptide establishes where the GH axis stands at baseline and helps a provider interpret any systemic changes during treatment.
• ALT and AST (liver enzymes): Standard safety baseline for any injectable compound with hepatic processing. Establishes pre-treatment liver function.
• Creatinine and eGFR: Kidney function baseline. Renal clearance affects peptide pharmacokinetics; impaired kidney function alters how injectable peptides are eliminated.
• CBC (complete blood count): General safety baseline for injectable therapy. Establishes hematologic status before treatment.
• hs-CRP: Systemic inflammation marker. Baseline hs-CRP provides context for any tissue-remodeling effect and establishes inflammatory status before treatment.

IGF-1, a comprehensive metabolic panel, and CBC establish the core baseline for any injectable peptide protocol. These reference points allow a provider to assess whether the compound is producing expected changes and to identify any safety signals before they become clinical problems.

How to Access Peptide Approaches for Skin Safely

Topical cosmetic peptide products are widely available over-the-counter. Selection should prioritize products that disclose the specific peptide ingredient with its INCI name, concentration range, and formulation details — because clinical evidence was generated for specific compounds at specific concentrations, not for the category in general.

Oral collagen peptide supplements are available without a prescription. The evidence base for hydration and elasticity is strongest for hydrolyzed collagen at doses studied in RCTs; evidence on collagen supplement time-course suggests that consistent use over 8 to 12 weeks is the minimum for assessing benefit.

There are no FDA-approved injectable peptides for skin indications. Historically, injectable GHK-Cu was available only through 503A compounding with a licensed provider's prescription; as of April 22, 2026, injectable GHK-Cu has been placed in FDA Category 2 and is no longer eligible for 503A compounding. Ash and colleagues, in a 2024 systematic review of topical exosome and peptide therapies published in Aesthetic Surgery Journal Open Forum, described the evolving evidence landscape for peptide-based skin therapies, noting that injectable approaches represent a newer and less thoroughly studied category than topical cosmetics. Readers considering any injectable peptide approach should discuss the current regulatory status and available evidence with a licensed clinician.

Understanding Your Baseline

Peptides for skin span a wider regulatory and evidence spectrum than almost any other category in consumer health. The same molecule name (GHK-Cu) describes a cosmetic ingredient regulated under one framework and a compounded injectable regulated under another — with different clinical evidence, different risks, and different access requirements for each form. Baseline biomarker data does not eliminate this complexity, but it gives a provider and patient a shared objective reference point from which to evaluate any approach.

That principle is central to Superpower's approach to preventive health. Whether the conversation leads to a topical cosmetic peptide, an oral supplement, or a provider-supervised injectable protocol, the starting point is understanding where your biology currently stands.

IMPORTANT NOTICE — Topical Cosmetic Peptide Ingredients

Palmitoyl pentapeptide (pal-KTTKS/Matrixyl), argireline (acetyl hexapeptide-3), topical GHK-Cu (copper tripeptide-1), acetyl tripeptide-30 citrulline, and related topical peptide ingredients discussed in this article are cosmetic ingredients regulated under FDA cosmetics law. They are not evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease or medical condition. This content is for educational purposes only and does not constitute medical advice.

IMPORTANT NOTICE — Oral Collagen Peptide Supplements

Oral hydrolyzed collagen peptides are dietary supplements regulated under the Dietary Supplement Health and Education Act (DSHEA). Statements about dietary supplements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. This content is for educational purposes only and does not constitute medical advice.

IMPORTANT SAFETY INFORMATION — Injectable GHK-Cu

Injectable GHK-Cu is not FDA-approved for any indication. As of April 22, 2026, GHK-Cu has been placed in FDA Category 2 of the 503A bulk drug substances list, meaning the FDA has identified significant safety risks and it is no longer eligible for compounding under Section 503A. Injectable GHK-Cu is therefore not legally available through traditional compounding pharmacies at this time. The safety and efficacy of injectable GHK-Cu for skin indications have not been established through adequate and well-controlled clinical trials. Clinicians considering any injectable peptide approach generally weigh contraindications including pregnancy or breastfeeding, history of hormone-sensitive malignancy, and known hypersensitivity to formulation components. For FDA guidance on compounded peptides and the bulk drug substance classification system, see the FDA's compounding resource center. For FDA-approved peptide drug labels, see dailymed.nlm.nih.gov.

Disclaimer: This article discusses topical cosmetic peptide ingredients, oral collagen peptide supplements, and the injectable form of GHK-Cu. Topical cosmetic peptides are not evaluated or approved as drugs. Oral collagen peptides are dietary supplements; statements have not been evaluated by the FDA. Injectable GHK-Cu is not FDA-approved and is available through compounding only. This educational content is editorially independent.